References
- Akabane T, Tabata K, Kadono K, et al. (2010). A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 38:308–16
- Burke MD, Vadi H, Jernström B, Orrenius S. (1977). Metabolism of benzo(a)pyrene with isolated hepatocytes and the formation and degradation of DNA-binding derivatives. J Biol Chem 252:6424–31
- Chao P, Uss AS, Cheng KC. (2010). Use of intrinsic clearance for prediction of human hepatic clearance. Expert Opin Drug Metab Toxicol 6:189–98
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
- Ding Q, Zhang Z, Liu JJ, et al. (2013). Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 56:5979–83
- Fitzsimmons ME, Collins JM. (1997). Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256–66
- Gibson GG, Plant NJ, Swales KE, et al. (2002). Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:165–206
- Higgins B, Glenn K, Walz A, et al. (2014). Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clin Cancer Res 20:3742–52
- Holland PM, Abramson RD, Watson R, Gelfand DH. (1991). Detection of specific polymerase chain reaction product by utilizing the 5′–3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 88:7276–80
- Jones HM, Parrott N, Jorga K, Lavé T. (2006). A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511–42
- Komura H, Iwaki M. (2008). Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 97:1775–800
- Kondo H, Watanabe T, Yokohama S, Watanabe J. (2003). Effect of food on gastrointestinal transit of liquids in cynomolgus monkeys. Biopharm Drug Dispos 24:141–51
- Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–94
- Matsubara T, Koike M, Touchi A, et al. (1976). Quantitative determination of cytochrome P-450 in rat liver homogenate. Anal Biochem 75:596–603
- Nishimura T, Amano N, Kubo Y, et al. (2007). Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Drug Metab Dispos 35:1275–84
- Nishimuta H, Sato K, Mizuki Y, et al. (2010). Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys. Drug Metab Dispos 38:1967–75
- Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–8
- Paine MF, Hart HL, Ludington SS, et al. (2006). The human intestinal cytochrome P450 “pie.”. Drug Metab Dispos 34:880–6
- Reddy MB, Connor A, Brennan BJ, et al. (2011). Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. Biopharm Drug Dispos 32:261–75
- Remmer H, Greim H, Schenkman JB, Eslabrook RW. (1967). Methods for the elevation of hepatic microsomal mixed functional oxidase levels and cytochrome P-450. Methods Enzymol 10:703–8
- Schmittgen TD, Livak KJ. (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101–8
- Takahashi M, Washio T, Suzuki N, et al. (2009). The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci 98:4343–53
- Thummel KE. (2007). Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest 117:3173–6
- Thummel KE, O'Shea D, Paine MF, et al. (1996). Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491–502
- Tovar C, Graves B, Packman K, et al. (2013). MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 73:2587–97
- Yang J, Jamei M, Yeo KR, et al. (2007). Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676–84